Many applications—from drug discovery and diagnostics to cell engineering and gene modulation—require delivering biomolecules into large numbers of cells and rapidly evaluating the outcomes. The ...

Cancer cells are relentless in their quest to grow and divide, often rewiring their metabolism and modifying RNA to stay one ...

In this video we electroplate SLA samples with Acid Copper and Bright Nickel, then test their tensile and ultimate strength ...

Rising global energy demands are pushing the limits of solar technology. Scientists in Sweden have now taken a major step ...

Third Person Shooters The "tactical enthusiasm" of Helldivers 2 players, by which Arrowhead means catapulting Hellbombs at Leviathan ships, is now canon: "Innovative Leviathan hunting techniques have ...

Some might say it looks like a finger. Others might see a worm. Scientists in the field often liken it to an antenna. The technical name is primary cilium. This slender, microscopic appendage juts out ...

Genentech is continuing its summer of downsizing and cost-cutting, this time with plans to terminate a cell therapy deal worth as much as $2 billion. The pact is with Adaptive Biotechnologies and ...

There are some things, from baking sourdough bread to binge-watching Tiger King, that worked great during the pandemic but don’t seem so appealing now. Target is one of them, but it doesn’t need to go ...

There is a surprising new claim about the Nintendo Switch 2’s capabilities. Deep Learning Super Sampling, is Nvidia’s proprietary upscaling technology. Nvidia has been upgrading DLSS so that other ...

WESTPORT, Conn. (WTNH) — Five people were arrested on Monday after allegedly using counterfeit bills in Westport. Westport police received multiple calls regarding a group of people attempting to use ...

Borrowing a cancer cell’s disguise, scientists shielded insulin-producing cells from attack by the immune system, a breakthrough that could pave the way for targeted type 1 diabetes treatments without ...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced it has completed the last ...